	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	2017 Mar 31	2018 Mar 31	R 2019 Mar 31	R 2020 Mar 31	2021 Mar 31	R 2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Total Revenue	125.66	162.65	185.34	97.67	85.32	64.96	47.17	43.63	42.47	71.22	85.14	115.45	152.57	145.99	150.62
Cost of Operating Revenue	104.34	141.16	144.58	97.65	77.78	61.99	47.87	38.05	30.29	49.93	56.77	81.93	107.86	103.79	108.56
Gross Profit	21.32	21.49	40.76	0.03	7.54	2.97	-0.70	5.58	12.18	21.28	28.37	33.52	44.71	42.20	42.06
Gross Margin	17.0	13.2	22.0	-	8.8	4.6	-1.5	12.8	28.7	29.9	33.3	29.0	29.3	28.9	27.9
Total Operating Expenses	115.90	161.29	171.49	121.32	89.66	74.99	86.28	60.18	44.51	65.40	78.67	103.52	145.46	138.35	140.74
Operating Profit	9.76	1.36	13.85	-23.64	-4.34	-10.03	-39.10	-16.55	-2.04	5.82	6.47	11.93	7.11	7.64	9.88
Operating Margin	7.8	0.8	7.5	-24.2	-5.1	-15.4	-82.9	-37.9	-4.8	8.2	7.6	10.3	4.7	5.2	6.6
Financing Income/(Expense) - Net	-8.38	-11.76	-13.21	-13.46	-12.96	-11.47	23.09	-2.13	-0.10	-0.74	-0.79	-0.52	-0.49	-1.25	-3.66
Profit before Taxes	5.37	5.49	2.49	6.07	-15.32	-20.36	-14.72	-18.29	-1.88	5.83	5.22	11.62	7.35	4.15	10.97
Income Taxes	3.47	1.48	1.05	-0.15	-0.18	-0.90	2.19	1.07	-	-	-	0.28	-	-	-0.13
Profit after Tax	1.84	3.96	1.40	6.18	-14.03	-19.09	-16.74	-18.87	-25.20	5.83	5.22	11.34	7.35	4.15	11.10
PAT Margin	1.5	2.4	0.8	6.3	-16.4	-29.4	-35.5	-43.3	-59.3	8.2	6.1	9.8	4.8	2.8	7.4
EPS - Basic - ex Extraordinary Items	10.01	21.24	7.52	33.11	-75.19	-119.80	-71.50	-120.94	-7.94	2.46	2.19	4.86	3.11	1.76	4.75
EPS - Diluted - ex Extraordinary Items	10.01	21.24	7.52	33.11	-75.19	-119.80	-71.50	-120.94	-7.94	2.46	2.19	4.86	3.11	1.76	4.69
EBIT	9.76	1.36	13.85	-23.64	-4.34	-10.03	-39.10	-16.55	-2.04	5.82	6.47	11.93	7.11	7.64	9.88
EBITDA	16.06	9.61	22.84	-17.66	0.52	-5.81	-35.13	-13.08	1.23	10.30	11.96	17.26	12.11	12.53	15.95
EBITDA Margin	12.8	5.9	12.3	-18.1	0.6	-8.9	-74.5	-30.0	2.9	14.5	14.0	15.0	7.9	8.6	10.6

Balance Sheet

Abridged

Understanding Balance Sheet

Bafna Pharmaceuticals Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	C 2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	C 2020 Mar 31	2021 Mar 31	R 2022 Mar 31	2023 Mar 31	C 2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	136.62	178.55	156.48	127.09	122.48	77.18	48.74	48.47	35.88	49.67	50.88	87.31	93.77	84.73	89.65
Long-Term Investments	-	-	-	16.90	16.90	51.93	44.20	32.95	-	-	0.42	-	0.70	0.00	0.96
Property Plant & Equipment - Net	55.68	54.69	53.35	54.53	52.57	48.58	44.86	37.02	35.18	36.80	38.85	40.23	50.71	66.09	84.92
Total Non-Current Assets	82.32	82.03	79.35	72.74	70.22	101.12	89.62	71.00	35.18	36.80	39.26	42.27	53.91	68.35	85.88
Total Assets	218.94	260.59	235.82	199.83	192.71	178.31	138.36	119.47	71.06	86.47	90.14	129.58	147.68	153.08	175.53
Total Current Liabilities	121.77	160.01	135.43	111.09	95.05	81.47	59.85	70.82	17.10	24.31	22.01	46.48	54.08	51.85	57.19
Long Term Debt	26.33	25.20	22.95	11.64	35.17	39.01	23.25	22.99	3.02	5.29	5.32	8.43	10.75	14.03	17.78
Total Non-Current Liabilities	32.55	32.27	30.65	16.03	39.91	54.72	41.31	29.80	3.02	5.39	6.17	9.65	12.76	16.42	22.19
Total Liabilities	154.32	192.28	166.08	127.12	134.95	136.20	101.16	100.62	20.12	29.69	28.18	56.13	66.84	68.27	79.38
Total Shareholders' Equity	63.82	67.45	68.86	71.78	57.75	42.67	37.93	19.06	50.95	56.77	61.96	73.45	80.84	84.81	96.15
Minority Interest	0.80	0.85	0.89	0.93	-	-0.55	-0.73	-0.21	-	-	-	-	-	-	-
Total Equity	64.62	68.30	69.75	72.71	57.75	42.11	37.20	18.85	50.95	56.77	61.96	73.45	80.84	84.81	96.15
Total Liabilities & Equity	218.94	260.59	235.82	199.83	192.71	178.31	138.36	119.47	71.06	86.47	90.14	129.58	147.68	153.08	175.53

Cash Flow

Abridged

Understanding Cash Flow Statement

Bafna Pharmaceuticals Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	C 2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	C 2017 Mar 31	2018 Mar 31	C 2019 Mar 31	C 2020 Mar 31	2021 Mar 31	C 2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	6.50	10.20	9.52	-35.70	-12.05	-16.15	-41.15	-14.85	-22.15	9.60	12.01	16.94	13.02	12.00	17.71
Working Capital - Increase/(Decrease)	14.75	14.91	-20.77	33.27	0.39	3.91	27.20	11.06	-12.17	-23.25	-2.36	-13.64	-5.72	7.53	-5.89
Net CF from Operating Activities	21.25	25.11	-11.25	-2.43	-11.66	-12.24	-13.96	-3.80	-34.32	-13.66	9.65	3.29	7.30	19.53	11.83
Capital Expenditures - Net	29.98	2.13	1.75	-33.32	2.31	0.08	-46.81	-4.60	1.43	6.09	7.54	8.02	15.68	21.80	24.88
Net CF from Investing Activities	-38.34	-6.49	-7.07	59.76	-0.75	-5.61	37.94	15.24	32.74	-5.38	-6.56	-7.52	-15.18	-21.30	-22.47
Dividends Paid - Cash - Total	-	1.30	-	-	-	-	-	-	-	-	-	-	-	-	-
Stock - Issuance/(Retirement) - Net	7.63	0.98	-	-	-	4.00	12.00	1.38	55.36	-	-	-	-	-	-
Debt - LT & ST - Issuance/(Retirement) - Total	-	0.04	-	-57.37	12.35	13.78	-35.69	-12.63	-43.24	12.37	-4.73	11.86	1.47	3.81	9.23
Net Cash Flow from Financing Activities	7.63	-0.02	0.05	-57.37	12.35	17.78	-23.69	-11.69	7.37	12.37	-4.73	11.86	1.47	3.81	9.23
Free Cash Flow to Equity	-8.73	23.03	-13.00	-26.47	-1.61	1.47	-2.83	-11.83	-78.99	-7.38	-2.61	7.14	-6.91	1.54	-3.82
Free Operating CF net dividend	-8.73	21.68	-13.00	-10.22	-13.96	-12.31	-14.08	-4.13	-35.75	-19.75	2.11	-4.92	-8.55	-2.33	-13.08
Free Operating CF	-8.73	22.98	-13.00	-10.22	-13.96	-12.31	-14.08	-4.13	-35.75	-19.75	2.11	-4.92	-8.55	-2.33	-13.08

Business Segment Analysis

FY End:

Mar 25

Bafna Pharmaceuticals Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Pharmaceuticals (100.0%)₹ 21.86 Cr

Revenue / Sales

Pharmaceuticals (100.0%)₹ 145.99 Cr

Assets

Pharmaceuticals (100.0%)₹ 153.08 Cr

Operating Income

Pharmaceuticals (100.0%)₹ 7.64 Cr

Regional Segment Analysis

FY End:

Mar 13

Bafna Pharmaceuticals Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

Asia (45.5%)₹ 75.97 CrIndia (33.5%)₹ 56.06 CrUnited Kingdom (20.7%)₹ 34.56 CrAfrica (0.3%)₹ 0.54 Cr

Historical Segment Analysis

Track how Bafna Pharmaceuticals Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2023 Mar 31	2024 Mar 31	2025 Mar 31

Pharmaceuticals	8	16	22

Frequently Asked Questions

What is the revenue of Bafna Pharmaceuticals Ltd.?

The latest trailing twelve month revenue of Bafna Pharmaceuticals Ltd. is ₹ 150.62 Cr, reflecting a 1-year growth of 3.17% and a 3-year CAGR of 9.27%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Bafna Pharmaceuticals Ltd.?

The latest trailing twelve month net profit (PAT) of Bafna Pharmaceuticals Ltd. is ₹ 11.10 Cr, with a 3-year earnings CAGR of -1.18%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Bafna Pharmaceuticals Ltd.?

The trailing twelve month EBITDA of Bafna Pharmaceuticals Ltd. is approximately ₹ 9.88 Cr (based on an operating margin of 6.56%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Bafna Pharmaceuticals Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Bafna Pharmaceuticals Ltd. is 4.69. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Bafna Pharmaceuticals Ltd.?

The debt-to-equity ratio of Bafna Pharmaceuticals Ltd. stands at 0.39. The interest coverage ratio is 2.70x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Bafna Pharmaceuticals Ltd.?

The estimated book value per share of Bafna Pharmaceuticals Ltd. is 40.64 (derived from a P/B ratio of 7.14 and market price of ₹ 290.20), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Bafna Pharmaceuticals Ltd.?

The trailing twelve month operating cash flow of Bafna Pharmaceuticals Ltd. is ₹ 11.83 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Bafna Pharmaceuticals Ltd. report consolidated or standalone financials?

Bafna Pharmaceuticals Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.